EGFR and neoplasm: Importantly, the combination of resveratrol and cetuximab significantly inhibited the growth of cetuximab-resistant tumor xenografts in nude mice without inducing systemic toxicity compared to resveratrol or cetuximab alone, and lead to a significant down-regulation of uPAR/integrinβ1/p-ERK1/2 (Fig. 5A,B), indicating that this combination may inhibit tumor growth in mice by suppressing two independent but convergent pathways (EGFR-dependent and uPAR-dependent pathways) simultaneously (Fig. 6B).